Specify a stock or a cryptocurrency in the search bar to get a summary
Klaria Pharma Holding AB
KLARKlaria Pharma Holding AB (publ.) operates as a pharmaceutical company. It develops Sumatriptan for the treatment of migraine. The company also develops Epinephrine/Adrenaline, which is in Phase I clinical trial for the treatment of acute allergic reaction. In addition, its pre-clinical product is Sirolimus for prevention of organ transplant rejection. Further, the company focuses on the commercialization of cannabis/cannabinoids. Klaria Pharma Holding AB (publ.) was incorporated in 2014 and is headquatered in Uppsala, Sweden. Address: Virdings Allé 2, Uppsala, Sweden, 754 50
Analytics
WallStreet Target Price
10.17 SEKP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures KLAR
Dividend Analytics KLAR
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History KLAR
Stock Valuation KLAR
Financials KLAR
Results | 2019 | Dynamics |